Is Posterior Tibial Nerve Stimulation Response Correlated with Sacral Neuromodulation outcome in Lower Urinary Tract Dysfunctions?

Alassiri A1, Al Shaikh A2, Dawagee A2, AlAmer A2, Alnasser A2, AlGhamdi S2, Alqahtani W2, Alabbad A2, Almousa R2, Aldossary N2

Research Type

Clinical

Abstract Category

Neurourology

Abstract 650
Open Discussion ePosters
Scientific Open Discussion Session 105
Thursday 8th October 2026
13:40 - 13:45 (ePoster Station 7)
Exhibition Hall
Neuromodulation Urgency Urinary Incontinence Voiding Dysfunction
1. King khalid university medical city, Saudi Arabia, 2. King Fahad Specialist Hospital, Eastern Health Cluster, Dammam, Saudi Arabia
Presenter
Links

Abstract

Hypothesis / aims of study
Percutaneous tibial nerve stimulation (PTNS) is often used as a less invasive step therapy before sacral neuromodulation (SNM). the objective of this study is to assess if a successful treatment with one neuromodulation modality corresponds with success in the other for various lower urinary tract dysfunctions.
Study design, materials and methods
A retrospective cohort study of patients who completed ≥6 PTNS sessions and underwent SNM Stage I. PTNS success was defined as >50% symptom improvement; SNM success as progression to full implant. Negative predictive value (NPV) of PTNS failure, correlation between PTNS and SNM outcomes, and subgroup analyses by urodynamic parameters (DOI vs. DO ) were performed. Univariate logistic regression explored additional predictors of SNM success.
Results
We found 22 patients, 4 (18%) achieved PTNS success and 15 (68%) achieved SNM success. The correlation between PTNS response and SNM success was negligible (p = 0.75). The NPV of PTNS failure was 33.3% (95% CI 13.3–59.0%), meaning 66.7% of PTNS failures still succeeded with SNM. In the OAB-wet subgroup (DO‐positive, n=3), SNM success was 100% regardless of PTNS response. In the OAB dry subgroup (DO‐negative, n=13), PTNS success was associated with a non‐significant higher SNM success rate (66.7% vs. 40.0%, p = 0.58).
Device reprogramming frequency in SNM implanted patient did not differ between PTNS responders and non‐responders. Univariate analysis identified detrusor overactivity (DO) as a potential predictor of SNM success ( p = 0.07).
Interpretation of results
PTNS response poorly predicts SNM success (phi=0.07). Two‑thirds of PTNS failures still achieved SNM success (NPV 33%). The wet phenotype (DO‑positive) showed universal SNM response. Thus, PTNS non‑response should not preclude an SNM trial, particularly in patients with urgency incontinence. Detrusor overactivity may be a stronger predictor than PTNS outcome.
Concluding message
PTNS response does not predict SNM success, and detrusor overactivity (OAB‑wet) may be a stronger indicator of SNM benefit. The high SNM success among PTNS failures (66.7% overall) is highlighted in the footnote, emphasising that PTNS failure should not preclude a trial of SNM.
Figure 1
Figure 2
Disclosures
Funding Neur-Urikigt Clinical Trial No Subjects Human Ethics Committee fk Helsinki not Req'd . Informed Consent Yes AI Other AI Usage AI
19/06/2026 05:56:29